# Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer

Source: https://onco.cc/key-papers/paper-cowan-xpert-bladder-monitor-bju-int-2021/  
OnCo record `paper-cowan-xpert-bladder-monitor-bju-int-2021` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A longitudinal validation of a five-marker urine RNA test for bladder cancer follow-up.

## Summary

The sensitivity for high-grade cancer was 87 per cent with a negative predictive value of 99 per cent.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: BJU International
- Year: 2021
- DOI: 10.1111/bju.15418
- Authors: Cowan B, Klein E, Jansz K, et al.
- Findings: High-grade sensitivity 87%, negative predictive value 99%.
- What it means: A negative urine result makes a high-grade recurrence unlikely.
- Caveats: Industry-sponsored.

## Sources

- Cowan et al., BJU Int 2021: https://doi.org/10.1111/bju.15418
- PubMed: https://pubmed.ncbi.nlm.nih.gov/33793062/

## Connected records

- cancers: [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid RNA biopsy (cell-free, vesicle and platelet RNA)](https://onco.cc/technologies/liquid-rna-biopsy/), [Urine tests for bladder cancer (cytology, FISH, RNA and methylation)](https://onco.cc/technologies/urine-bladder-cancer-tests/)
- drugs: [Xpert Bladder Cancer Monitor](https://onco.cc/drugs/xpert-bladder-cancer-monitor/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-cowan-xpert-bladder-monitor-bju-int-2021.json